MedTrace Logo

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

NCT03501940 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-01-21

No results posted yet for this study

Summary

This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography (PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how far the disease has spread.

Conditions

  • Prostate Adenocarcinoma
  • PSA Level Greater Than 0.2
  • PSA Level Greater Than or Equal to Two
  • PSA Progression
  • Recurrent Prostate Carcinoma

Interventions

PROCEDURE

Computed Tomography

Undergo 18F-DCFPyL PET/CT

RADIATION

Fluorine F 18 DCFPyL

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo 18F-DCFPyL PET/CT

Sponsors & Collaborators

  • Andrei Iagaru

    lead OTHER

Principal Investigators

  • Andrei Iagaru · Stanford Cancer Institute Palo Alto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03501940 on ClinicalTrials.gov